Fuente: FierceBiotech Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each program that Jazz options.